Related posts
Nervous markets await NvidiaThis summary was created by AI, based on 24 opinions in the last 12 months.
Merck & Company (MRK) is widely recognized for its flagship cancer drug, Keytruda, which has significantly contributed to its revenues and is expected to remain a critical asset until its patent expiration in 2028. Despite concerns regarding potential pressure from U.S. healthcare reforms and the looming off-patent status of Keytruda, many analysts express optimism about the company's future, citing its robust pipeline and recent acquisitions as key drivers for growth. The stock is perceived to be trading at attractive valuation levels, with a decent dividend yield around 3% and a price-to-earnings ratio that reflects a cheap entry point amid broader market concerns. Analysts maintain a positive outlook on MRK, suggesting that it is likely to overcome political and competitive challenges due to its strong R&D capabilities and historical performance of successful drugs. Overall, MRK is seen as a buy opportunity by several experts, even amid its current market fluctuations.
It is best in class. It is a large manufacturer of vaccines but the primary driver is an immune therapy drug that is used across many types of cancers and has 200 ongoing trials. It is coming off patent later in the decade. The vaccine take-up could lead to slower growth but this is a shorter term issue. Buy 24 Hold 8 Sell 0
(Analysts’ price target is $124.60)Off highs. 2025 provides a broad opportunity in healthcare. Big cancer drug Keytruda coming off patent in 2028, but that's built into the stock price trading at 10x PE. Other drugs in the pipeline to fill in the space. Track record of successful and profitable blockbusters. Yield is 3%.
(Analysts’ price target is $126.88)The new US administration is talking tough about health cost controls, certainly more extreme than in the past. MRK's Keytruda is a blockbuster drug that has a few years to go before the patent ends. Healthcare has been out of favour the past year, but he recommends holding on.
Pharma is ~90% of revenue, smaller segment is animal care. Pulled back about 23% from recent peak in June. Yield is 3%, has grown at 5% compound pace over last 5 years. So total compounded shareholder return ~10% over the last decade. Pullback probably buyable. Steady, non-cyclical, a need not a want.
Risks include lower guidance on Gardasil (second-biggest drug) sales in China, coming off patent in 2028. Keytruda (biggest drug) also coming off patent then. Those two together account for just over 50% of revenues. Need to fill hole in pipeline either through R&D or M&A.
Merck & Company is a American stock, trading under the symbol MRK-N on the New York Stock Exchange (MRK). It is usually referred to as NYSE:MRK or MRK-N
In the last year, 54 stock analysts published opinions about MRK-N. 18 analysts recommended to BUY the stock. 18 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Merck & Company.
Merck & Company was recommended as a Top Pick by on . Read the latest stock experts ratings for Merck & Company.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
54 stock analysts on Stockchase covered Merck & Company In the last year. It is a trending stock that is worth watching.
On 2025-04-02, Merck & Company (MRK-N) stock closed at a price of $86.5.
Likes he CEO and company, though the company is hung up on Keytruda is the only big drug they have. He likes the stock at this level.